

# Investigational therapy for patients with malignant pleural effusion from **NSCLC & Mesothelioma**

**MITOPE**  
CLINICAL TRIAL

For healthcare professionals



## Seeking Patients

Malignant Pleural Mesothelioma patients with Pleural Effusion who

1. Have progressed after > 1 prior line of treatment or
2. Are newly diagnosed, treatment naive; Window of Opportunity (WoO)

NSCLC patients with metastatic disease to the lungs with MPE and can benefit from systemic combination treatment

## About The Study

We're seeking participants to join an open-label, Phase II Expansion Study (MITOPE), aimed at assessing the efficacy and safety of a novel investigational anticancer agent – RSO-021 – in patients with advanced cancer and few remaining treatment options.

## RSO-021 Localized Therapy

- Allows for direct contact between the drug therapy and the metastatic tumour(s) of the pleura.
- Results in an increased concentration of drug in the local environment
- Therapy is delivered through an intrapleural catheter (IPC)



## For more information

Call: +44 20 8135 8316  
mitope@RSOncology.com  
www.RSOncology/MITOPE

©2024 RS Oncology. All Rights Reserved. Ver1 | 2.24

[Reference: #NCT05278975](#)

